Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The NCT03650894 record now presents details of a Phase 2 breast cancer study, including its treatments, eligibility criteria, locations, and outcome measures. It also includes study status and record dates, collaborators, and related resources.
    Difference
    52%
    Check dated 2026-11-11T02:00:33.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-11-04T00:40:30.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    A site-wide notice about NIH terminology changes appears above the error page, and the footer revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:37:25.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-07T00:57:44.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error instead of the study record content. Previous content including locations, institutions, and study details has been removed and replaced by a simple error page with only a Home link.
    Difference
    19%
    Check dated 2026-09-23T00:39:31.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page's revision label was updated from Revision: v3.6.6 to Revision: v3.7.0, indicating a maintenance/upgrade of the ClinicalTrials.gov interface for this record. The study information and controls remain the same.
    Difference
    0.1%
    Check dated 2026-09-15T23:52:47.000Z thumbnail image

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.